SPRO — Spero Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1701108 ·
Last close
$0.90
Market Cap
$52.51M
52W High
$3.08
52W Low
$0.88
ADV30
366,985
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -6,913,000 | -44,278,000 | 110,026,000 | 107,928,000 | 109,245,000 |
| Jun 2026 | 0 | — | -9,926,000 | -9,552,000 | 52,766,000 | 50,774,000 | 8,562,000 |
| Mar 2026 | 258,000 | — | -7,538,000 | -7,203,000 | 59,021,000 | 56,129,000 | 6,087,000 |
| Dec 2025 | 39,658,000 | — | 31,405,000 | 31,520,000 | 68,919,000 | 40,265,000 | 9,898,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$19,580,000
Investing CF
—
Financing CF
—
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.11
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-467,821,000
Inventory
—
Receivables
$25,000
ST Investments
—
EBIT TTM
$6,612,000
Pretax Income TTM
$7,644,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$46,997,000
EBITDA
—
Free Cash Flow
$28,848,500
Enterprise Value
$9,503,827
Total Cash
$50,774,000
Total Debt
$2,043,000
Shares Out
58,264,577
Trailing EPS
$-0.50
Book Value
$1.05
ROE
19.2%
ROA
7.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 59,619,000 | 7,159,000 | 8,572,000 | 68,919,000 | 9,898,000 | 59,021,000 | -12,624,000 |
| Dec 2024 | 27,396,000 | -72,484,000 | -68,566,000 | 110,543,000 | 64,420,000 | 46,123,000 | -23,444,000 |
| Dec 2023 | 96,735,000 | 26,787,000 | 22,806,000 | 182,390,000 | 75,496,000 | 106,894,000 | -32,995,000 |
| Dec 2022 | 48,579,000 | -30,567,000 | -46,415,000 | 124,802,000 | 48,868,000 | 75,934,000 | -7,731,000 |
TTM Snapshot
Revenues TTM
$46,997,000
NetIncome TTM
$7,383,000
OpCashFlow TTM
—
Assets (Latest)
$52,766,000
Forward EPS
$-0.98
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.50 · spot: $0.87 · call volume: 11 · put volume: 1,020
Expected Move to 2027-01-15:
±$0.65
(74.37%) —
implied range
$0.22 –
$1.52
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GANX | Gain Therapeutics, Inc. | $52.54M | $1.18 | — |
| AZR | Azora Therapeutics, Inc. (DE) | $52.36M | $3.66 | — |
| IBIO | iBio, Inc. | $52.71M | $0.75 | — |
| XLO | Xilio Therapeutics, Inc. | $53.26M | $7.54 | — |
| IBO | IMPACT BIOMEDICAL INC. | $53.31M | $6.17 | — |
News headlines (Yahoo Finance, 1h cache)
Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
2026-11-12 21:05 · Yahoo
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 21:05 · Yahoo
Spero Therapeutics to Present at Investor Conferences in November
2026-11-02 21:05 · Yahoo
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
2026-10-26 12:00 · Yahoo
Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
2026-10-21 06:02 · Yahoo
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
2026-10-15 20:05 · Yahoo
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | Delv
2026-10-12 17:00 · Yahoo
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:05 · Yahoo
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 20:01 · Yahoo
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
2026-08-19 21:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.